Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|24|11|1050-1065

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.24, Iss.11, 2017-05, pp. : 1050-1065

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia: Current and Emerging Treatments

By Martin Alissa   Morgan Elaine   Hijiya Nobuko  

Pediatric Drugs, Vol. 14, Iss. 6, 2012-12 ,pp. : 377-387

Adis International

Access to resources Recommend Favorite

The Multimodal Treatment of Acromegaly: Current Status and Future Perspectives

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 14, Iss. 3, 2014-09 ,pp. : 169-181

Bentham Science Publishers

Access to resources Recommend Favorite

Clofarabine: In Pediatric Patients with Acute Lymphoblastic Leukemia

By Curran Monique P.   Perry Caroline M.  

Pediatric Drugs, Vol. 7, Iss. 4, 2005-01 ,pp. : 259-264

Adis International

Access to resources Recommend Favorite

Acute Lymphoblastic Leukemia: Optimizing Treatment Strategies in Children

By Vora A.  

Pediatric Drugs, Vol. 4, Iss. 6, 2002-01 ,pp. : 405-416

Adis International

Access to resources Recommend Favorite

Current Therapeutic Strategies and Future Perspectives for the Treatment of Venous Thromboembolism

By  

Current Pharmaceutical Design, Vol. 16, Iss. 31, 2010-10 ,pp. : 3475-3477

Bentham Science Publishers

Access to resources Recommend Favorite